NASDAQ: LYRA - Lyra Therapeutics, Inc.

Rentabilidad a seis meses: -95.6%
Sector: Healthcare

Calendario de promoción Lyra Therapeutics, Inc.

Horario avanzado gráfico sencillo
Financial Markets by TradingView

Acerca de la empresa

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration.

Más detalles
The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Añadir a la lista de comparación
Añadir a la lista de vigilancia
Añadir al portafolio
Añadir aviso de precio

Выручка 0.000285
EBITDA -0.0165
Число акций ао 0.0498 млрд
P/S 192.29
P/BV 1.28
EV/EBITDA 0.393
Цена ао 6.13
ISIN US55234L1052
Сайт https://lyratherapeutics.com
Валюта usd
IPO date 2020-05-01
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Cambio de precio por día: 0% (0.2284)
Cambio de precio por semana.: +2.33% (0.2232)
Cambio de precio por mes: -18.43% (0.28)
Cambio de precio en 3 meses.: -20.94% (0.2889)
Cambio de precio en seis meses: -95.6% (5.19)
Cambio de precio por año: -93.55% (3.54)
Cambio de precio en 3 años.: -97.39% (8.74)
Cambio de precio desde principios de año.: -93.16% (3.34)
Todos los parámetros

Subestimación

Nombre Significado Calificación
P/S 159.19 1
P/BV 2.77 6
P/E 0 0
EV/EBITDA -3.87 0
Total: 3.5

Eficiencia

Nombre Significado Calificación
ROA, % -43.96 0
ROE, % -70.1 0
Total: 0

Dividendos

Nombre Significado Calificación
Div yield, % 0 0
DSI 0 0
Total: 0

Deber

Nombre Significado Calificación
Debt/EBITDA -0.412 10
Total: 10

Impulso de crecimiento

Nombre Significado Calificación
Rentabilidad Revenue, % 29.83 4
Rentabilidad Ebitda, % 295.45 10
Rentabilidad EPS, % -51.03 0
Total: 6.8
Más detalles

Instituciones Volumen Compartir, %
Perceptive Advisors LLC 12757562 21.35
Nantahala Capital Management, LLC 8100436 13.56
Vestal Point Capital, LP 3000000 5.02
Point72 Asset Management, L.P. 3000000 5.02
Citadel Advisors Llc 2861255 4.79
Samsara BioCapital, LLC 2780261 4.65
VR Adviser, LLC 2575593 4.31
Rosalind Advisors, Inc. 1888720 3.16
PURA VIDA INVESTMENTS, LLC 1413242 2.37
Ikarian Capital, LLC 1254384 2.1

ETF Compartir, % Rentabilidad del año, % Dividendos, %
ProShares Hedge Replication ETF 0.00008 6.8665973306333 1.47892
iShares Micro-Cap ETF 0.00348 43.316995205115 1.54048
iShares Russell 2000 Growth ETF 0.00096 47.42032299557 0.6026
ProShares UltraPro Russell2000 0.0003 125.96465921385 1.47873
Vanguard Russell 2000 Growth ETF 0 46.764050831914 0.60264
Vanguard Russell 2000 ETF 0 41.410408042578 1.48801



Supervisor Título profesional Pago año de nacimiento
Dr. Harlan W. Waksal M.D. Executive Chairman 210.06k 1953 (71 año)
Dr. Maria Palasis Ph.D. CEO, President & Director 942.7k 1965 (59 años)
Dr. Carmichael S. Roberts Jr., Ph.D. Co-Founder N/A 1969 (55 años)
Mr. Jason Cavalier CFO, Treasurer & Secretary 464.11k 1973 (51 año)
Mr. Ray Knox Vice President of Operations N/A
Ms. Vineeta Belanger Ph.D. Senior Vice President of Clinical Affairs N/A
Mr. Ronan P. O'Brien J.D. Chief Legal Officer 1973 (51 año)
Dr. Robert Richard Ph.D. Senior Vice President of Technical Operations 1958 (66 años)
Dr. Robert Kern M.D. Chief Clinical Advisor
Ms. Gloria Cosgrove Senior Vice President of Quality

DIRECCIÓN: United States, Watertown. MA, 480 Arsenal Way - abrir en mapas de google, abrir mapas de Yandex
Sitio web: https://lyratherapeutics.com